Figure 3
FSL–1, a TLR2/6 ligand, demonstrates radiomitigation properties. Toxicity was tested in male C57BL/6 mice, comparing physiologic water (NT) to 0.25 mg/kg FSL–1 treatment. (a) Survival, (b) clinical score, and (c) percent body weight change of mice were monitored over 30 days. Sex independency was tested by treating female C57BL/6 mice exposed to 9.2 Gy TBI with physiological water (NT) or 0.25 mg/kg FSL–1 given 24 hours post TBI. (d) Survival, (e) clinical score and (f) percent body weight change of female mice were assessed for 30 days. The effectiveness of FSL–1 treatment was compared by delivering physiological water (NT) or 0.25 mg/kg FSL–1 at 24 or 48 hours after 8.8 or 9.2 Gy TBI. (g) Survival and (h) percent body weight change were assessed for 30 days. Efficacy of FSL–1 combined with antibiotics treatment was evaluated by delivering physiological water (NT) or 0.25 mg/kg FSL–1 at 24 hours after 8.8 Gy TBI. On days 4 to 30 post TBI, ciprofloxacin was provided in autoclaved acidified water ad libitum from sipper tubes and also in wetted feed. Controls received no ciprofloxacin support, but did receive acidified water and moistened regular feed. (i) Survival, (j) clinical score and (k) percent body weight change were assessed for 30 days. Data (mean ± s.e.m.) are representative of 2 independent experiments with n = 5 to 15 as indicated in panel legends. *P < 0.05, **P < 0.01 or ****P < 0.0001 between treated and TBI, NT mice, with color representing treatment group. Arrows indicate time post TBI in which remaining mice in group began to recover.
